SG10201803370XA - Conjugates of somatostatin and its analogs - Google Patents

Conjugates of somatostatin and its analogs

Info

Publication number
SG10201803370XA
SG10201803370XA SG10201803370XA SG10201803370XA SG10201803370XA SG 10201803370X A SG10201803370X A SG 10201803370XA SG 10201803370X A SG10201803370X A SG 10201803370XA SG 10201803370X A SG10201803370X A SG 10201803370XA SG 10201803370X A SG10201803370X A SG 10201803370XA
Authority
SG
Singapore
Prior art keywords
somatostatin
conjugates
analogs
hydrogels
carriers
Prior art date
Application number
SG10201803370XA
Inventor
Eric L Schneider
Brian Hearn
Gary Ashley
Daniel Santi
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of SG10201803370XA publication Critical patent/SG10201803370XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Abstract

OF THE DISCLOSURE CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed. Figure 39
SG10201803370XA 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs SG10201803370XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361894226P 2013-10-22 2013-10-22

Publications (1)

Publication Number Publication Date
SG10201803370XA true SG10201803370XA (en) 2018-06-28

Family

ID=52993525

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603115YA SG11201603115YA (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs
SG10201803370XA SG10201803370XA (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201603115YA SG11201603115YA (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs

Country Status (10)

Country Link
US (2) US10086049B2 (en)
EP (1) EP3060230A4 (en)
JP (1) JP2016534064A (en)
KR (1) KR20160075665A (en)
CN (1) CN106232131A (en)
AU (1) AU2014340095A1 (en)
CA (1) CA2928407A1 (en)
MX (1) MX2016005285A (en)
SG (2) SG11201603115YA (en)
WO (1) WO2015061503A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118902A1 (en) * 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
CN111065623A (en) * 2017-05-24 2020-04-24 德克萨斯州大学系统董事会 Linker for antibody drug conjugates
EP3684414A4 (en) * 2017-09-19 2021-06-09 Immunwork Inc. Pharmaceutical constructs with enhanced binding affinity with albumin
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
KR20220074897A (en) * 2019-09-30 2022-06-03 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 Protein-macromolecule conjugates and methods of use thereof
EP4073064A4 (en) * 2019-12-11 2024-01-24 Massachusetts Gen Hospital Methods for cell imaging
CN114409736B (en) * 2022-01-28 2023-09-15 中国科学院精密测量科学与技术创新研究院 Phasing arrangement medium based on amphiphilic oligopeptide and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
CN1507357A (en) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ Method and compositions for enhanced delivery of bioactive molecules
EP2457564A1 (en) 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
KR20110025974A (en) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. Octreotide implant having a release agent
DK2306986T3 (en) 2008-06-26 2018-06-18 Prolynx Llc PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
US8640315B1 (en) 2009-10-28 2014-02-04 Robert E. Nikkel Rotating adapter assembly
PT2523653T (en) * 2010-01-13 2018-06-28 Ipsen Pharma Sas Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN103025164B (en) * 2010-05-05 2017-03-08 普罗林科斯有限责任公司 The control release of medicine from solid support
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc Controlled drug release from dendrimers
CN103025165B (en) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 From the controlled release of macromolecular conjugates
WO2013036847A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Hydrogels with biodegradable crosslinking
MX350929B (en) 2011-12-05 2017-09-26 Camurus Ab Robust controlled-release peptide formulations.

Also Published As

Publication number Publication date
CN106232131A (en) 2016-12-14
US20180296648A1 (en) 2018-10-18
US10086049B2 (en) 2018-10-02
JP2016534064A (en) 2016-11-04
EP3060230A4 (en) 2017-06-14
SG11201603115YA (en) 2016-05-30
AU2014340095A1 (en) 2016-05-26
US10413594B2 (en) 2019-09-17
CA2928407A1 (en) 2015-04-30
MX2016005285A (en) 2016-10-28
KR20160075665A (en) 2016-06-29
WO2015061503A1 (en) 2015-04-30
US20160271227A1 (en) 2016-09-22
EP3060230A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
SG10201803370XA (en) Conjugates of somatostatin and its analogs
SG10201809428UA (en) Insulin receptor partial agonists
IN2013KO01129A (en)
JO3755B1 (en) Testosterone formulations
MX357675B (en) Anti-jagged anitbodies and methods of use.
AU2014224814A8 (en) Novel halogen-substituted compounds
NZ630549A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
IN2013KO01130A (en)
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
EP3747444A3 (en) Use of sedoheptulose as a nutritional supplement
EP3305267A4 (en) Fifth generation fu's needle
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA99989U (en) 4-diamino-5-imino-8-oxo,8,9,10-tetrahydro-5h-pyrido[2',3':2,3]thiopyrano[4, 5-b]pyridine
UA103911U (en) Vasodilating substance
UA76716U (en) 5,7-dimethyl-2-oxo-6-phenylazo-thiazolo[4,5-b]pyridine-3-ylhydrazones acetates exhibiting antiexudative action
UA99994U (en) 4-diamino,8,9,10-tetrahydro-5h-pyrido[2',3':2,3]thiopyrano[4,5-b]pyridine
IN2012DE01204A (en) "shikhar technology"
UA99991U (en) 11-di(2-etilfenil)-13-(2-methoxyphenyl)-8-thioxo-3,5,7,11-tetraazatricyclo[7.3.1.0,7,9-dikarbonitril
UA99988U (en) 4-diamino4-dimethoxyphenyl)-8-oxo-3-cyano-7,8,9,10-tetrahydro-5h-pyrido[2',3':2,3]thiopyrano[4,5-b]pyridine
MX2015001134A (en) Therapeutic compounds.
UA94338U (en) 2-oxo-5-phenyl-2,3-dihydro-thiazole[4,5-b]pyridine-7-carboxyl acid which reveals anti-exudate effect.
UA99992U (en) 2,34-tetrahydropyridin-6-thiolate